Latest Regulatory News

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.

Brookside Energy Ltd delivered a standout quarter in Q4 2024, posting record production growth and a 667% jump in operating cash flow, while completing a major development project ahead of schedule and under budget.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Donaco International posted modest revenue and EBITDA gains in Q2 FY2025, alongside a stronger cash position, while navigating regulatory uncertainties in Southeast Asia.

Tigers Realm Coal is finalising the sale of its Russian subsidiaries for US$49 million, pending crucial Presidential approval, while navigating recent leadership shifts.

St Barbara has secured A$100 million to fast-track its Simberi Sulphides project, aiming to bring forward production by up to five months, even as Q2 gold output fell short of expectations due to operational challenges.

Meeka Metals reports steady progress on its Murchison Gold Project, with key infrastructure and processing plant expansions on track for first gold production by mid-2025.

Omni Bridgeway Limited reports strong investment proceeds and new commitments in the first half of FY25, alongside significant cost savings and the imminent financial close of Fund 9 with Ares Management.

Almonty Industries has locked in final commitments for an AUD 18.45 million equity placement from existing shareholders, aiming to strengthen its financial position and cover offer costs. The placement includes warrants and options, with closing pending regulatory approval.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.